POSTERS ASCO 2024

Cáncer gastrointestinal

Colorrectal y anal

Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.

Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.

Abstract: 3584 Poster Bd #: 247

Poster

Descargar

Autor
Josep Tabernero, MD, PhD, FASCO

Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO)

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON